Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Depreciation & Amortization (CF): 2020-2025

Historic Depreciation & Amortization (CF) for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $501,000.

  • Janux Therapeutics' Depreciation & Amortization (CF) fell 1.76% to $501,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 0.29%. This contributed to the annual value of $2.1 million for FY2024, which is 5.37% up from last year.
  • According to the latest figures from Q3 2025, Janux Therapeutics' Depreciation & Amortization (CF) is $501,000, which was down 7.39% from $541,000 recorded in Q2 2025.
  • Over the past 5 years, Janux Therapeutics' Depreciation & Amortization (CF) peaked at $541,000 during Q2 2025, and registered a low of $9,000 during Q1 2021.
  • In the last 3 years, Janux Therapeutics' Depreciation & Amortization (CF) had a median value of $510,000 in 2024 and averaged $506,909.
  • Per our database at Business Quant, Janux Therapeutics' Depreciation & Amortization (CF) surged by 2,600.00% in 2021 and then fell by 3.58% in 2024.
  • Quarterly analysis of 5 years shows Janux Therapeutics' Depreciation & Amortization (CF) stood at $64,000 in 2021, then soared by 529.69% to $403,000 in 2022, then soared by 31.76% to $531,000 in 2023, then fell by 3.58% to $512,000 in 2024, then declined by 1.76% to $501,000 in 2025.
  • Its Depreciation & Amortization (CF) was $501,000 in Q3 2025, compared to $541,000 in Q2 2025 and $519,000 in Q1 2025.